相关实验视频
Updated: May 9, 2026

07:40
Multi-Modal Home Sleep Monitoring in Older Adults
Published on: January 26, 2019
了解"嵌入式药物化":关于晚年使用安眠药的案例研究
Georgia Smith1, Hannah Farrimond1
1University of Exeter, UK.
Health (London, England : 1997)
|February 12, 2026
概括
长期使用安眠药在老年人中持续存在,原因是对睡眠的深刻情感需求,压倒性的担忧. 这个这个这个这个这个
科学领域:
- 社会学 社会学 社会学
- 老年学是一门学科.
- 药学研究 药学研究
背景情况:
- 老年人服用安眠药与跌倒和认知能力下降等不良影响有关.
- 尽管有减少处方的指导方针,长期使用仍然在老年人中很常见.
- 社会学研究显示,人们对晚年睡眠辅助剂的依赖存在矛盾和不安.
研究的目的:
- 探索老年人持续长期使用安眠药的原因.
- 了解睡眠药物的使用如何嵌入到老年人的生活中.
- 调查情绪需求,感知必要性和对睡眠辅助剂的持续依赖之间的相互作用.
主要方法:
- 有关面试和日记的定性研究,涉及38名65岁及以上的英国成年人.
- 参与者使用安眠药的平均持续时间为17年.
- 分析的重点是了解尽管表达了担忧,但使用的持续性.
主要成果:
- 参与者表达了道德上的担忧,但优先考虑了对睡眠的深刻情感需求.
- 睡眠药物被视为唯一有效的补救措施,导致了"嵌入式制药化".
- 用户采用了积极的 (采购,储存) 和被动的 (避免审查) 策略来维持使用,由必要性和习惯驱动.
结论:
- 老年人长期使用安眠药是通过"嵌入式制药化"的过程来维持的,在这种过程中,药物成为情感生活和身份的组成部分.
- 对睡眠辅助剂的感知必要性和情感依赖超过了减少或避免它们的表达愿望.
- 了解这些轨迹对于解决药物使用持续超过最初处方的情况至关重要.
相关概念视频
Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

